Experts debate second-line tivozanib for advanced renal cell carcinoma, weighing PFS gains, tolerability, and whether continuing immunotherapy adds real benefit.
|Articles|January 31, 2014
Abiraterone and Enzalutamide for mCRPC
Author(s)Charles Ryan, MD
Charles Ryan, MD, Associate Clinical Professor, Department of Medicine (Hematology/Oncology), University of California, San Francisco, discusses the utility of abiraterone and enzalutamide for patients with metastatic castration-resistant prostate cancer.
Advertisement
Clinical Pearls
Charles Ryan, MD, Associate Clinical Professor, Department of Medicine (Hematology/Oncology), University of California, San Francisco, discusses the utility of abiraterone and enzalutamide for patients with metastatic castration-resistant prostate cancer.
- The phase III PREVAIL study looked at enzalutamide versus placebo in chemotherapy-naïve, asymptomatic patients with metastatic castration-resistant prostate cancer
- There was a statistically significant survival benefit and positive prolongation of radiographic progression-free survival in favor of enzalutamide
- Dr. Ryan believes these data will drive the eventual use of this therapy in the chemotherapy-naïve population
- Physician prescribing preferences will ultimately determine how abiraterone and enzalutamide are used
<<<
Advertisement
Related to this article
Preview the late-breaking studies at ESMO Congress 2026, from KRAS inhibitors and ADCs to bispecifics and perioperative immunotherapy across tumor types.
FDA expands nogapendekin alfa inbakicept plus BCG use to high-grade papillary-only BCG-unresponsive NMIBC, offering durable control and strong cystectomy-avoidance outcomes.
Experts weigh IO-TKI vs dual immunotherapy for metastatic ccRCC, highlighting rapid symptom relief, bone/brain response, survival outcomes, and toxicity tradeoffs.
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Dostarlimab Receives FDA Approval for MSI-H/dMMR Locally Advanced Rectal Cancer
2
Dr Bazhenova on the Updated FDA Label for Taletrectinib in ROS1+ NSCLC
3
MC001 Receives FDA Fast Track Designation in Pancreatic Cancer
4
Oncologists Debate Role of On-Body Injector for Transplant-Ineligible Myeloma
5